Benzinga's Top Pre-Market NASDAQ Gainers

Acorda Therapeutics Inc ACOR shares advanced 20.07% to $32.07 in the pre-market session. The Committee for Medicinal Products for Human Use of the European Medicine Agency recommended conditional marketing authorization of FAMPYRA. Opnext Inc OPXT shares advanced 16.58% to $2.18 in the pre-market session. OPXT reported its Q4 net income at $9.0 million, versus a net loss of $10.2 million, in the year-ago quarter. Yongye International Inc YONG climbed 5.11% to $3.70 in the pre-market session. YONG responded to allegations in purported analyst reports. Human Genome Sciences Inc HGSI jumped 3.65% to $29 in the pre-market session. The European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion for the company's lupus treatment Benlysta. Read more from Benzinga's Markets.